- Home
- »
- Medical Devices
- »
-
Established Vs Emerging Players In Surgical Robotics IndustryGVR Report cover
Product Pipeline Analysis: Established Vs Emerging Players In Surgical Robotics Industry
1.1 Surgical Robots Market
The global surgical robots market size was estimated at USD 3.92 billion in 2023 and is expected to grow at a CAGR of 9.5% from 2024 to 2030. The surgical robots market serves a multitude of applications, such as orthopedics, neurology, urology, gynecology, laparoscopy, and various others. This trend report from the GVR research team is anticipated to deliver key qualitative insights regarding the product pipelines acquired by established market players and emerging ventures.

Factors such as the growing adoption of automated surgical instruments, the rising number of knee and hip replacement surgeries due to increasing osteoporosis and arthritis cases, and the increasing preference for precise & accurate minimal invasive surgeries. For instance, according to an article published by NCBI in February 2022, around 240 million people worldwide have symptomatic osteoporosis, including 18% of women and 10% of men aged 60 and above.
1.2 Surgical Robots Market Key Market Players
Higher favorable outcomes compared to open surgeries and shorter periods of hospitalization and quicker recoveries fuel the demand for robotic-assisted surgeries, which is anticipated to boost market growth. Furthermore, technological advancements and incorporating artificial intelligence (AI) and machine learning (ML) in robotic surgeries drive market growth.

Furthermore, the global surgical robots’ market is expected to witness various changes as major healthcare players are anticipated to enter the industry. For instance, in January 2024, MassRobotics, a robotics hub that educates and brings investments, robotics initiatives, and companies along with partners Mitsubishi Electric, FESTO, MITRE, and Novanta, announced the Healthcare Robotics Startup Catalyst III Cohort to revolutionize the healthcare robotics sector.

1.3 Surgical Robots Market, Established vs Emerging Players
Verticals
Established Player
Emerging Player
Company Name
Intuitive Surgical
AcuSurgical
Overview
Intuitive Surgical develops, manufactures, and markets a robotic system to aid minimally invasive surgery. Globally, the company has successfully installed over 8,600 da Vinci surgical systems in hospitals worldwide, with the U.S. accounting for more than 5,000 of those installations and a growing number in emerging markets. Intuitive has over 12,100 employees and a presence in more than 60 countries.
AcuSurgical is a France-based surgical robotics company. The company develops retinal microsurgery devices used in eye operations. The company's device is a robotic surgical assistant that aids in the treatment of retinal diseases such as age-related macular degeneration, helping surgeons increase the precision of current procedures, augment visualization, and filter tremors.
Established Year
1995
2020
Products
The company has the following products,
- Da Vinci Xi
- Da Vinci X
- Da Vinci SP
- Ion
Application
The Da Vinci system is used in a wide range of surgeries. However, it is mostly used for gastrointestinal, urological, and gynecological surgeries. In addition, more than 70% of Da Vinci procedures are hysterectomies and prostatectomies.
Partnerships in terms of technology, distribution
salesforce
American Cancer Society
MERIEUX EQUITYPARTNERS
biologie, ingeniene elimagene de la greffe de Comee
Pipeline Product
Da Vinci 5
Luca Robotic Surgery Platform
Growth Strategies
Intuitive Surgical invests heavily in R&D, enhancing its digital tools and platforms. The company's most significant development was submitting its 510(k) application for da Vinci 5, a next-generation multi-port platform, in 2023.
The total volume of surgeries performed across different specialties using da Vinci surgical systems in the U.S. are as follows,

1.4 Surgical Robot Companies
1.4.1 Intuitive Surgical

1.4.2 AcuSurgical

1.4.3 Pipeline Product Analysis
Verticals
Established Player
Emerging Player
Company Name
Intuitive Surgical
AcuSurgical
Pipeline Product
da Vinci 5
Luca Robotic Surgery Platform
Benefits
- Improved precision and accuracy
- First-of-its-kind force-sensing technology
- Next-generation 3D display and image processing
- Meaningful throughput and workflow enhancements
- Advanced data capabilities and expanded computing power
- Greater surgeon comfort
- Advances procedural capabilities while providing improved control for the surgeon
- Improved precision and accuracy
- Enables new treatments for retinal diseases, such as Age-Related Macular Degeneration (AMD)
Clinical Trials Data
Ohio State leads the testing and trials of the new surgical robot da Vinci 5 developed by Intuitive Surgical. The trials were conducted at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital, Richard J. Solove Research Institute (OSUCCC-James), and the Ohio State University College of Medicine. Moreover, clinical trials with patient involvement have confirmed the safety and efficacy of the da Vinci 5. In March 2024, the company received U.S. FDA approval for da Vinci 5.
In March 2024, AcuSurgical completed its first clinical case, successfully and safely performed at Ghent University Hospital in Belgium by Dr. Fanny Nerinckx.
1.5 Surgical Robot Market Position Analysis

1.6 Innovative Trends in Surgical Robotics Industry
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.